“Patient-Reported Outcomes with Roflumilast Foam 0.3% in Patients with Psoriasis of the Scalp and Body in the Phase 3 ARRECTOR Trial” (2025) SKIN The Journal of Cutaneous Medicine, 9(2), p. s525. doi:10.25251/skin.10.supp.525.